Diabetic Neuropathy: Pathophysiology Review
- PMID: 38558164
- DOI: 10.1007/s11916-024-01243-5
Diabetic Neuropathy: Pathophysiology Review
Abstract
Purpose of review: Diabetic neuropathy is a debilitating complication of diabetes mellitus that affects millions of individuals worldwide. It is characterized by nerve damage resulting from prolonged exposure to high blood glucose levels. Diabetic neuropathy may cause a range of symptoms, including pain, numbness, muscle weakness, autonomic dysfunction, and foot ulcers, potentially causing significant impairment to the quality of life for those affected. This review article aims to provide a comprehensive overview of the pathophysiology of diabetic neuropathy. The etiology of diabetic neuropathy will be discussed, including risk factors, predisposing conditions, and an overview of the complex interplay between hyperglycemia, metabolic dysregulation, and nerve damage. Additionally, we will explore the molecular mechanisms and pathways of diabetic neuropathy, including the impact of hyperglycemia on nerve function, abnormalities in glucose metabolism, the role of advanced glycation end products (AGEs), and inflammatory and immune-mediated processes. We will provide an overview of the various nerve fibers affected by diabetic neuropathy and explore the common symptoms and complications associated with diabetic neuropathy in the pain medicine field.
Recent findings: This review highlights advances in understanding the pathophysiology of diabetic neuropathy as well as reviews potential novel therapeutic strategies and promising areas for future research. In conclusion, this review article aims to shed light on the pathophysiology of diabetic neuropathy, its far-reaching consequences, and the evolving strategies for prevention and management. In understanding the mechanisms of diabetic neuropathy and the ongoing research in this area, healthcare professionals can better serve patients with diabetes, ultimately improving well-being and reducing complications.
Keywords: Autonomic dysfunction; Diabetes; Neuropathy; Painful neuropathy; Peripheral neuropathy.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
[Diabetic somatic polyneuropathy. Pathogenesis, clinical manifestations and therapeutic concepts].Fortschr Neurol Psychiatr. 2000 Jun;68(6):278-88. doi: 10.1055/s-2000-11535. Fortschr Neurol Psychiatr. 2000. PMID: 10923253 Review. German.
-
Complications: neuropathy, pathogenetic considerations.Diabetes Care. 1992 Dec;15(12):1902-25. doi: 10.2337/diacare.15.12.1902. Diabetes Care. 1992. PMID: 1464245 Review.
-
[Diabetic neuropathy].Pol Merkur Lekarski. 2007 Jan;22(127):66-9. Pol Merkur Lekarski. 2007. PMID: 17477095 Review. Polish.
-
Assessment for Diabetic Neuropathy: Treatment and Neurobiological Perspective.Curr Diabetes Rev. 2025;21(6):12-31. doi: 10.2174/0115733998290606240521113832. Curr Diabetes Rev. 2025. PMID: 38798207 Review.
-
Diabetic neuropathy: cellular mechanisms as therapeutic targets.Nat Rev Neurol. 2011 Sep 13;7(10):573-83. doi: 10.1038/nrneurol.2011.137. Nat Rev Neurol. 2011. PMID: 21912405 Review.
Cited by
-
Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight.Pathophysiology. 2025 Feb 13;32(1):9. doi: 10.3390/pathophysiology32010009. Pathophysiology. 2025. PMID: 39982365 Free PMC article. Review.
-
Predicting diabetic retinopathy stages using a simple nerve conduction measuring device, DPNCheck®: a retrospective observational study.Front Clin Diabetes Healthc. 2025 Jul 16;6:1590407. doi: 10.3389/fcdhc.2025.1590407. eCollection 2025. Front Clin Diabetes Healthc. 2025. PMID: 40740761 Free PMC article.
-
Flavonoids regulating NLRP3 inflammasome: a promising approach in alleviating diabetic peripheral neuropathy.Inflammopharmacology. 2025 May;33(5):2231-2262. doi: 10.1007/s10787-025-01729-7. Epub 2025 Apr 9. Inflammopharmacology. 2025. PMID: 40205269 Free PMC article. Review.
-
Senegenin ameliorates diabetic encephalopathy via promoting mitophagy and repressing NLRP3 inflammasome activation.Psychopharmacology (Berl). 2025 Apr 26. doi: 10.1007/s00213-025-06796-w. Online ahead of print. Psychopharmacology (Berl). 2025. PMID: 40281338
-
Pericytes and Diabetic Microangiopathies: Tissue Resident Mesenchymal Stem Cells with High Plasticity and Regenerative Capacity.Int J Mol Sci. 2025 Jun 1;26(11):5333. doi: 10.3390/ijms26115333. Int J Mol Sci. 2025. PMID: 40508141 Free PMC article. Review.
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
-
- Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817–24. https://doi.org/10.1212/wnl.43.4.817 . - DOI - PubMed
-
- Sloan G, Shillo P, Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabetes Res Clin Pract. 2018;144:177–91. https://doi.org/10.1016/j.diabres.2018.08.020 . - DOI - PubMed
-
- Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2017;40(1):136–54. https://doi.org/10.2337/dc16-2042 . - DOI - PubMed
-
- Motataianu A, Maier S, Bajko Z, Voidazan S, Balasa R, Stoian A. Cardiac autonomic neuropathy in type 1 and type 2 diabetes patients. BMC Neurol. 2018;18(1):126. https://doi.org/10.1186/s12883-018-1125-1 . - DOI - PubMed - PMC
-
- Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. https://doi.org/10.1007/s11892-014-0528-7 . - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials